利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.028 秒)

    Immunological detection method for triazines
    1.
    发明授权
    Immunological detection method for triazines 失效
    三嗪免疫检测方法

    公开(公告)号：US5573922A

    公开(公告)日：1996-11-12

    申请号：US235393

    申请日：1994-04-29

    申请人： Eva Hoess ,  Erasmus Huber ,  Christine Markert-Hahn ,  Wolfgang Rollinger

    发明人： Eva Hoess ,  Erasmus Huber ,  Christine Markert-Hahn ,  Wolfgang Rollinger

    IPC分类号： G01N33/53 ,  G01N33/545

    CPC分类号： G01N33/5308 ,  Y10S436/815

    摘要： An immunological method for the determination of triazine and triazine derivatives by a competitive immunoassay in which the sample and labelled atrazine compete for a polyclonal antibody which is bound to a solid phase before, during or after the immunological reaction, the immunological complex binds to the solid phase, the solid phase and unbound labelled atrazine are separated and the label in the solid or liquid phase is determined as a measure of the content of triazine and triazine derivatives, which is characterized in that polyclonal antibodies which were obtained by immunization with a 4-alkylamino-S-triazine are used and a conjugate of a label and 4-amino-S-triazine which is bound to the label via the 6 position is used as the labelled atrazine. Triazine and triazine derivatives can be determined simultaneously using this method.

    摘要翻译： 通过竞争性免疫测定法测定三嗪和三嗪衍生物的免疫学方法，其中样品和标记的莠去津竞争在免疫反应之前，期间或之后与固相结合的多克隆抗体，免疫复合物结合固体 分离固相和未结合标记的莠去津，固定或液相中的标记作为三嗪和三嗪衍生物含量的量度来确定，其特征在于通过用4- 使用烷基氨基-S-三嗪，并且通过6位与标记结合的标记物和4-氨基-S-三嗪的缀合物用作标记的莠去津。 可以使用该方法同时测定三嗪和三嗪衍生物。

    ASSESSING RISK OF DISEASE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS
    3.
    发明申请
    ASSESSING RISK OF DISEASE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS 有权
    评估炎症性疾病患者的疾病进展风险

    公开(公告)号：US20090270272A1

    公开(公告)日：2009-10-29

    申请号：US12412840

    申请日：2009-03-27

    申请人： Johann Karl ,  Veit Peter Grunert ,  Wolfgang Rollinger ,  Norbert Wild

    发明人： Johann Karl ,  Veit Peter Grunert ,  Wolfgang Rollinger ,  Norbert Wild

    IPC分类号： C40B30/04 ,  C40B40/10

    CPC分类号： G01N33/564 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4737 ,  G01N2333/5412 ,  G01N2800/102

    摘要： Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.

    摘要翻译： 公开了一种辅助进一步评估患有类风湿性关节炎患者的体外方法。 该方法特别用于评估RA患者是否处于疾病进展的风险。 该方法例如通过分析生物化学标记来实施，包括在样品中测量至少C反应蛋白（CRP）和白细胞介素-6的浓度，并将确定的浓度与RA的潜在快速进展形式的可能性相关联。 患有快速进展疾病的高风险患者可能是需要治疗的患者，或者如果已经需要治疗，需要进行不同的和更有效的治疗。 本发明还涉及在评估类风湿性关节炎患者中使用包含C-反应蛋白和白细胞介素-6的标记物片，并分别教导了用于实施本发明方法的蛋白质阵列装置和试剂盒。

    Method for providing diagnosis of cancer using seprase as a marker
    9.
    发明授权
    Method for providing diagnosis of cancer using seprase as a marker 有权
    使用seprase作为标记提供癌症诊断的方法

    公开(公告)号：US08980573B2

    公开(公告)日：2015-03-17

    申请号：US12791946

    申请日：2010-06-02

    申请人： Wolfgang Rollinger ,  Johann Karl ,  Jarema Peter Kochan ,  Markus Roessler ,  Michael Tacke

    发明人： Wolfgang Rollinger ,  Johann Karl ,  Jarema Peter Kochan ,  Markus Roessler ,  Michael Tacke

    IPC分类号： C12Q1/37 ,  G01N33/574

    CPC分类号： G01N33/57423 ,  G01N33/57407 ,  G01N33/57419 ,  G01N33/57473 ,  G01N2333/96411

    摘要： The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

    摘要翻译： 本发明涉及一种协助癌症评估的方法。 它公开了使用人成纤维细胞活化蛋白（FAP / seprase）作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。 这些特定的癌症类型是例如食管，头颈癌，胃癌，胆管癌，胰腺癌，肾癌，子宫颈癌，卵巢癌，乳腺癌，膀胱癌，子宫内膜癌或前列腺癌。 此外，它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。

    Assessing risk of disease progression in rheumatoid arthritis patients
    10.
    发明授权
    Assessing risk of disease progression in rheumatoid arthritis patients 有权
    评估类风湿关节炎患者疾病进展的风险

    公开(公告)号：US08058013B2

    公开(公告)日：2011-11-15

    申请号：US12412840

    申请日：2009-03-27

    申请人： Johann Karl ,  Veit Peter Grunert ,  Wolfgang Rollinger ,  Norbert Wild

    发明人： Johann Karl ,  Veit Peter Grunert ,  Wolfgang Rollinger ,  Norbert Wild

    IPC分类号： G01N33/53

    CPC分类号： G01N33/564 ,  G01N33/6869 ,  G01N33/6893 ,  G01N2333/4737 ,  G01N2333/5412 ,  G01N2800/102

    摘要： Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.

    摘要翻译： 公开了一种辅助进一步评估患有类风湿性关节炎患者的体外方法。 该方法特别用于评估RA患者是否处于疾病进展的风险。 该方法例如通过分析生物化学标记来实施，包括在样品中测量至少C反应蛋白（CRP）和白细胞介素-6的浓度，并将确定的浓度与RA的潜在快速进展形式的可能性相关联。 患有快速进展疾病的高风险患者可能是需要治疗的患者，或者如果已经需要治疗，需要进行不同的和更有效的治疗。 本发明还涉及在评估类风湿性关节炎患者中使用包含C-反应蛋白和白细胞介素-6的标记物片，并分别教导了用于实施本发明方法的蛋白质阵列装置和试剂盒。